Advanced Filters
noise

thrombocytopenic Clinical Trials

A listing of thrombocytopenic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 67 clinical trials
V Veronique Kouassi

Observatory of Immunological Thrombopenic Purpura in the Brest Region

Database of patients with ITP, diagnosed, treated and followed in the Brest University Hospital.

years of age All Phase N/A
H Hongmei Jing, Professor

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).

18 years of age All Phase 2

Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia

This is a single-arm, open-label,phase I clinical study to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection in treatment of refractory systemic lupus erythematosus-related immune thrombocytopenia.

18 - 70 years of age All Phase 1
M Ming Hou, PhD

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.

18 years of age All Phase 1/2
D Debbie C Jiang, MD

Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

Individuals with immune thrombocytopenia (ITP) frequently report difficulties with attention and memory. The main question this study seeks to answer is: Do patients with ITP have evidence of cognitive impairment as detected by a cognitive function test battery? To address this issue, participants will take a cognitive function test and …

18 years of age All Phase N/A
X Xiao Hui Zhang, MD

Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy

This is a prospective, randomized, open-label, multicenter clinical trial study to compare the efficacy and safety of prednisone plus IVIg to prednisone monotherapy in the treatment of immune thrombocytopenia (ITP) in pregnancy.

18 - 50 years of age Female Phase 2
Y Yan Shi

A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)

This is a Phase 2, open-label, randomized, multicenter study to assess the efficacy and safety of DZD8586 in patients with primary immune thrombocytopenia (ITP). The target population of this study is patients with primary ITP who had failed to respond or relapsed after receiving at least one standard therapy. Participants …

18 years of age All Phase 2

Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia

Immune thrombocytopenia (ITP) are antibody-mediated disorders in which platelets are destroyed mainly through activating immunoglobulin (IgG) Fc receptors on phagocytes in the spleen and liver, eventually resulting in thrombocytopenia Acute phase proteins (APP) are inflammation markers that exhibit significant changes in serum concentration during inflammation. These are also important mediators …

1 - 50 years of age All Phase N/A
A Alessandra Borchiellini

Biologic Characterization of Patients With ITP

This is a no-profit, multicenter, biological, non-pharmacologic study aimed to characterize from a biological point of view previously untreated primary ITP patients. To this end, peripheral blood, fecal and bone marrow samples will be collected at baseline and at 30 days and 180 days after treatment initiation - for each …

18 years of age All Phase N/A
A Ana Clara Kneese, PhD

V-IMMUNE® for Immune Thrombocytopenia

This is a multicenter, prospective clinical trial evaluating the efficacy and safety of V-IMMUNE®, a 5% human normal immunoglobulin formulation administered intravenously, for the treatment of immune thrombocytopenia (ITP) in patients aged ≥1 year. The primary objective is to assess the proportion of patients achieving a platelet count ≥50,000/mm³ on …

1 years of age All Phase 3

Simplify language using AI